GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk Safety and reactogenicity data are consistent ...

This is a news collection page for Darwin. Check this page for latest news headlines covering major stories, events from Darwin and surrounding Northern Territory. Get breaking news faster than ...

That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial. The trial initially enrolled about ...

(Reuters) – U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions ...

(Reuters) – U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

Additional data from the phase 3 trial showed the vaccine came with a 94.1% effectiveness in preventing severe RSV when people got it during the first season and 64.2% a year later, the company ...

Across the entire time period, one dose of Arexvy was 63% effective against RSV broadly, and 67% effective against severe disease, GSK said. However, the shot’s efficacy waned, falling to an estimated ...

LONDON (Reuters) – Pfizer on Monday won a bid in a London court to invalidate two of GSK’s patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a ...

LONDON (Reuters) – Pfizer on Monday won a bid in a London court to invalidate two of GSK’s patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are ...

It had a weaker-than-hoped launch of its respiratory syncytial virus (RSV) vaccine and clinical data from an obesity pill it was developing has been disappointing. CEO Bourla has also spent some $ ...

The president of the National Institute of Health Doutor Ricardo Jorge (INSA) has assured that from a “technical and laboratory point of view” Portugal is prepared for the respiratory syncytial virus ...